Inorg. Chem. 2008, 47, 2916-2918
Model Studies of Azide Binding to Functional Analogues of CcO
James P. Collman,* Abhishek Dey, Richard A. Decréau, and Ying Yang
Department of Chemistry, Stanford UniVersity, Stanford, California 94305
Received November 21, 2007
N3- binding to a functional model of CcO is investigated in its
Fe3+, Fe3+Cu+, and Fe3+Cu2+ forms. A combination of EPR and
FTIR indicates that N3- binds in a bridging mode in the bimetallic
sites and signature N3- bands are identified for several forms of
N3- binding to the site. The presence of the distal metal increases
the binding affinity of N3-. This bridging enables antiferromagnetic
interaction between the two metal centers in the Fe3+Cu2+ state,
which results in an EPR-silent ground state.
a and CuA reduced) are yet unexplored. Synthetic biomi-
metic model complexes provide a controlled environment
for studying these key interactions that take place in a protein
active site. Thus, there is a need for a systematic study of
N3- binding to the CcO active site model that will serve as
a reference for analyzing spectroscopic data obtained in
protein active sites.
Several synthetic CcO models have been reported in the
5
-
past decade, and one of them has been used to model N3
binding.6 Unfortunately, in the absence of FTIR data, the
presence of multiple N3 -bound forms, and the lack of O2
-
Cytochrome c oxidase (CcO) is the terminal electron donor
to oxygen in mitochondria, reducing it to H2O. This generates
a proton gradient that drives ATP synthesis.1 The O2
reduction occurs at the heterobimetallic active site of CcO
consisting of a heme a3 and a CuB center within 5 Å.2a–c
The reaction mechanism of this fundamentally important
reduction activity of this complex, it is hard to correlate those
results to the ones obtained in CcO. Recently, one synthetic
model complex has been shown to have O2-reducing activity,
under physiological conditions, comparable to the parent
enzyme (Scheme 1).7a–c In this study, we show that this
-
functional model can be used to investigate N3 binding to
-
enzyme and its interactions with small molecules (e.g., N3 ,
the CcO active site. We use EPR and FTIR techniques to
characterize different modes of N3- binding that helps gain
insight into the origin of noncompetitive inhibition of CcO
by these anionic ligands.8
CO, and NO) have been a focus of major research for several
decades.1,3 In particular, the nature of its interaction with
-
its inhibitor N3 has been investigated using Fourier trans-
form (FTIR), electron paramagnetic resonance (EPR), and
The monometallic Fe3+ complex can be synthesized by
oxidizing the Fe2+ complex with ferrocinum tetrafluoroborate
(Fc+) in dichloromethane (CH2Cl2). The mixed-valent (in
the active site) Fe3+Cu+ state has not been well characterized
in CcO9 or in any other model systems.7b It can be obtained
by adding 1 equiv of Cu2+ to a Fe2+ complex in a CH2Cl2
solution, whereupon FeII gets oxidized to Fe3+ and the
resulting Cu+ binds to the distal pocket of the model (Figure
S1 in the Supporting Information). It can also be synthesized
by adding 1 equiv of Cu+ to a Fe3+ complex. The addition
resonance Raman techniques.4a–c It is generally accepted that
-
one or two N3 ’s can bind either in a bridging or in a terminal
manner to the resting oxidized state of the active site
(Fe3+Cu2+). However, unambiguous assignment of the
spectroscopic data is generally complicated by spectroscopic
features from heme a and CuA centers (also present in the
-
enzyme). Furthermore, the role of the CuB center in N3
-
binding to the CcO active site and the possibility of N3
binding to a possible mixed-valent form (i.e., Fe3+Cu+ or
Fe2+Cu2+ forms of these complexes, not Fe3+Cu2+ with heme
*
To whom correspondence should be addressed. E-mail:
(5) (a) Liu, J.-G.; Naruta, Y.; Tani, F.; Chishiro, T.; Tachi, Y. Chem.
Commun. 2004, 120. (b) Liu, J.-G.; Naruta, Y.; Tani, F. Angew. Chem.,
Int. Ed. 2005, 44, 1836. (c) Kim, E.; Kamaraj, K.; Galliker, B.; Rubie,
N. D.; Moenne-LoCcOz, P.; Kaderli, S.; Zuberbuhler, A. D.; Karlin,
K. D. Inorg. Chem. 2005, 44, 1238.
(1) Ferguson-Miller, S.; Babcock, G. T. Chem. ReV. 1996, 96, 2889.
(2) (a) Iwata, S.; Ostermeier, C.; Ludwig, B.; Michel, H. Nature 1995,
376, 660. (b) Yoshikawa, S.; Shinzawa-Itoh, K.; Nakashima, R.;
Yaono, R.; Yamashita, E.; Inoue, N.; Yao, M.; Fei, M. J.; Libeu, C. P.;
Mizushima, T.; Yamaguchi, H.; Tomizaki, T.; Tsukihara, T. Science
1998, 280, 1723. (c) Fei, M. J.; Yamashita, E.; Inoue, N.; Yao, M.;
Yamaguchi, H.; Tsukihara, T.; Shinzawa-Ito, K.; Nakashima, R.;
Yoshikawa, S. Acta Crystallogr., Sect. D 2000, 56, 529.
(3) Collman, J. P.; Boulatov, R.; Sunderland, C. J.; Fu, L. Chem. ReV.
2004, 104, 561–88.
(6) Dallacosta, C.; Alves, W. A.; da Costa Ferreira, A. M.; Monzani, E.;
Casella, L. Dalton Trans. 2007, 2197.
(7) (a) Collman, J. P.; Sunderland, C. J.; Boulatov, R. Inorg. Chem. 2002,
41, 2282. (b) Collman, J. P.; Decréau, R. A.; Yan, Y.; Yoon, J.;
Solomon, E. I. J. Am. Chem. Soc. 2007, 129, 5794–5795. (c) Collman,
J. P.; Devaraj, N. K.; Decréau, R. A.; Yang, Y.; Yan, Y.-L.; Ebina,
W.; Eberspacher, T. A.; Chidsey, C. E. D. Science 2007, 315, 1565.
(8) N3- does not bind to the fully reduced active form of CcO. Petersen,
L. C. Biochim. Biophys. Acta 1977, 460, 299.
(4) (a) Vamvouka, M.; Muller, W.; Ludwig, B.; Varotsis, C. J. Phys.
Chem. B 1999, 103, 3030. (b) Tsubaki, M.; Yoshikawa, S. Biochem-
istry 1993, 32, 174. (c) Li, W. B.; Palmer, G. Biochemistry 1993, 32,
1833.
(9) Babcock, G. T.; Vickery, L. E.; Palmer, G. J. Biol. Chem. 1978, 253,
2400.
2916 Inorganic Chemistry, Vol. 47, No. 8, 2008
10.1021/ic702294n CCC: $40.75 2008 American Chemical Society
Published on Web 03/25/2008